VYNE Therapeutics Inc.(VYNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VYNE VYNE Therapeutics Inc.

Market Closed 12-20 16:00:00 EST

2.50

+0.11

+4.60%

盘后2.50

+0.000.00%

17:45 EST

High2.55	Low2.36	Vol34.73K
Open2.36	D1 Closing2.39	Amplitude7.95%
Mkt Cap36.88M	Tradable Cap25.86M	Total Shares14.75M
T/O85.83K	T/O Rate0.34%	Tradable Shares10.34M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"VYNE","market":"US","secType":"STK","nameCN":"VYNE Therapeutics Inc.","latestPrice":2.5,"timestamp":1734728400000,"preClose":2.39,"halted":0,"volume":34731,"hourTrading":{"tag":"盘后","latestPrice":2.5,"preClose":2.5,"latestTime":"17:45 EST","volume":11,"amount":28.01,"timestamp":1734734739755},"delay":0,"floatShares":10343744,"shares":14751433,"eps":-0.858797,"marketStatus":"Market Closed","change":0.11,"latestTime":"12-20 16:00:00 EST","open":2.36,"high":2.55,"low":2.36,"amount":85829.042793,"amplitude":0.079498,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.858797,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1734944400000},"marketStatusCode":7,"adr":0,"listingDate":1516856400000,"exchange":"NASDAQ","adjPreClose":2.39,"postHourTrading":{"tag":"盘后","latestPrice":2.5,"preClose":2.5,"latestTime":"17:45 EST","volume":11,"amount":28.01,"timestamp":1734734739755},"volumeRatio":0.5145440063481425,"impliedVol":3.8705,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/VYNE/wiki","defaultTab":"wiki","newsList":[{"id":"2491735274","title":"VYNE Therapeutics Sees Strong Shareholder Support for Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2491735274","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491735274?lang=en_us&edition=fundamental","pubTime":"2024-12-13 05:35","pubTimestamp":1734039336,"startTime":"0","endTime":"0","summary":"VYNE Therapeutics ( ($VYNE) ) just unveiled an announcement. VYNE Therapeutics’ stockholders approved an amendment to the 2023 Equity Incentive Pla...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vyne-therapeutics-sees-strong-shareholder-support-for-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vyne-therapeutics-sees-strong-shareholder-support-for-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","VYNE"],"gpt_icon":0},{"id":"2484471673","title":"BTIG Initiates VYNE Therapeutics at Buy With $8 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2484471673","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484471673?lang=en_us&edition=fundamental","pubTime":"2024-11-18 22:19","pubTimestamp":1731939542,"startTime":"0","endTime":"0","summary":"BTIG Initiates VYNE Therapeutics at Buy With $8 Price Target","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VYNE"],"gpt_icon":0},{"id":"2484262950","title":"Vyne Therapeutics Inc : Btig Initiates Coverage With Buy Rating; Price Target $8","url":"https://stock-news.laohu8.com/highlight/detail?id=2484262950","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484262950?lang=en_us&edition=fundamental","pubTime":"2024-11-18 20:17","pubTimestamp":1731932222,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nFWN3MP15W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","VYNE"],"gpt_icon":0},{"id":"2484628400","title":"VYNE Therapeutics initiated with a Buy at BTIG on I&I potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2484628400","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484628400?lang=en_us&edition=fundamental","pubTime":"2024-11-18 19:15","pubTimestamp":1731928515,"startTime":"0","endTime":"0","summary":"BTIG initiated coverage of VYNE Therapeutics (VYNE) with a Buy rating and $8 price target VYNE is pioneering the development of BET inhibitors in l...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vyne-therapeutics-initiated-with-a-buy-at-btig-on-ii-potential?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vyne-therapeutics-initiated-with-a-buy-at-btig-on-ii-potential?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","VYNE"],"gpt_icon":0},{"id":"2482423869","title":"VYNE Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags","url":"https://stock-news.laohu8.com/highlight/detail?id=2482423869","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482423869?lang=en_us&edition=fundamental","pubTime":"2024-11-09 21:09","pubTimestamp":1731157757,"startTime":"0","endTime":"0","summary":"NasdaqCM:VYNE Earnings and Revenue History November 9th 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 10.0%. Earnings per share  missed analyst estimates by 23%.Looking ahead, revenue is forecast to grow 94% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in the US.The company's shares are up 19% from a week ago.We should say that we've discovered 6 warning signs for VYNE Therapeutics (3 are significant!) that you should be aware of before investing here.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vyne-therapeutics-third-quarter-2024-130917221.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VYNE"],"gpt_icon":0},{"id":"2482481842","title":"Vyne Therapeutics Inc  expected to post a loss of 25 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2482481842","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482481842?lang=en_us&edition=fundamental","pubTime":"2024-11-09 00:31","pubTimestamp":1731083497,"startTime":"0","endTime":"0","summary":"Vyne Therapeutics Inc  expected to post a loss of25cents a share - Earnings Preview Vyne Therapeutics Inc VYNE.OQ VYNE.O is expected to show a rise in quarterly revenue when it reports  results  for t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nL8N3MF2R6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYNE"],"gpt_icon":0},{"id":"2481129027","title":"Vyne Therapeutics Price Target Maintained With a $5.75/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2481129027","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481129027?lang=en_us&edition=fundamental","pubTime":"2024-11-08 18:21","pubTimestamp":1731061260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VYNE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 08, 2024 05:21 ET (10:21 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYNE","LENZ"],"gpt_icon":0},{"id":"2481182392","title":"VYNE Therapeutics: Robust Pipeline and Financial Stability Underpin Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2481182392","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481182392?lang=en_us&edition=fundamental","pubTime":"2024-11-07 23:15","pubTimestamp":1730992523,"startTime":"0","endTime":"0","summary":"Analyst Rami Katkhuda from LifeSci Capital maintained a Buy rating on VYNE Therapeutics (VYNE – Research Report) and keeping the price target at $6...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/vyne-therapeutics-robust-pipeline-and-financial-stability-underpin-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/vyne-therapeutics-robust-pipeline-and-financial-stability-underpin-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYNE"],"gpt_icon":0},{"id":"2481118280","title":"VYNE Therapeutics: Promising Clinical Progress and Financial Stability Support Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2481118280","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481118280?lang=en_us&edition=fundamental","pubTime":"2024-11-07 23:05","pubTimestamp":1730991911,"startTime":"0","endTime":"0","summary":"Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on VYNE Therapeutics (VYNE – Research Report), retaining the price target of $5...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/vyne-therapeutics-promising-clinical-progress-and-financial-stability-support-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/vyne-therapeutics-promising-clinical-progress-and-financial-stability-support-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYNE","PRGS"],"gpt_icon":0},{"id":"2481678902","title":"VYNE Therapeutics Q3 2024 GAAP EPS $(0.29) Misses $(0.23) Estimate, Sales $121.000K Beat $110.000K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2481678902","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481678902?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:19","pubTimestamp":1730985586,"startTime":"0","endTime":"0","summary":"VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.23) by 26.09 percent.  The company reported quarterly sales of $121.000 thousand which","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41806039/vyne-therapeutics-q3-2024-gaap-eps-0-29-misses-0-23-estimate-sales-121-000k-beat-110-000k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"VYNE Therapeutics Q3 2024 GAAP EPS $(0.29) Misses $(0.23) Estimate, Sales $121.000K Beat $110.000K Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYNE"],"gpt_icon":0},{"id":"2481902676","title":"VYNE Therapeutics Q3 EPS $(0.29) Misses $(0.23) Estimate, Sales $121.00K Beat $110.00K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2481902676","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481902676?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:19","pubTimestamp":1730985551,"startTime":"0","endTime":"0","summary":"VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.23) by 26.09 percent. This is a 83.43 percent increase over losses of $(1.75) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41806001/vyne-therapeutics-q3-eps-0-29-misses-0-23-estimate-sales-121-00k-beat-110-00k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYNE"],"gpt_icon":0},{"id":"2481011489","title":"BRIEF-VYNE Therapeutics Q3 Basic EPS USD -0.29","url":"https://stock-news.laohu8.com/highlight/detail?id=2481011489","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481011489?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:00","pubTimestamp":1730984448,"startTime":"0","endTime":"0","summary":"Nov 07 (Reuters) - VYNE Therapeutics Q3 EPS from cont ops USD -0.29. * Q3 revenue USD 121 thousand * Q3 net income USD -12.157 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["USD","VYNE","BAS"],"gpt_icon":0},{"id":"2481901480","title":"Vyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2481901480","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481901480?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:00","pubTimestamp":1730984405,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nTUA1QVKPF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","VYNE"],"gpt_icon":0},{"id":"2481901253","title":"Vyne Therapeutics Q3 EPS From Cont Ops USD -0.29","url":"https://stock-news.laohu8.com/highlight/detail?id=2481901253","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481901253?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:00","pubTimestamp":1730984403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nPLXC000B5:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VYNE","BK4007"],"gpt_icon":0},{"id":"2481901232","title":"Vyne Therapeutics Q3 Revenue USD 121 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2481901232","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481901232?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:00","pubTimestamp":1730984403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nPLXC000B5:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VYNE","BK4007"],"gpt_icon":0},{"id":"2470831781","title":"We Think VYNE Therapeutics (NASDAQ:VYNE) Needs To Drive Business Growth Carefully","url":"https://stock-news.laohu8.com/highlight/detail?id=2470831781","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470831781?lang=en_us&edition=fundamental","pubTime":"2024-09-26 18:39","pubTimestamp":1727347142,"startTime":"0","endTime":"0","summary":"We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com?Given this risk, we thought we'd take a look at whether VYNE Therapeutics  shareholders should be worried about its cash burn. For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth . We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.When Might VYNE Therapeutics Run Out Of Money?VYNE Therapeutics' cash burn of US$27m is about the same as its market capitalisation of US$27m. Given just how high that expenditure is, relative to the company's market value, we think there's an elevated risk of fundi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/think-vyne-therapeutics-nasdaq-vyne-103902272.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NDAQ","LU2210150020.SGD","LU2210149790.SGD","SQQQ","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4112","IE00BKPKM429.USD","BK4588","NQmain","LU2095319765.USD","MNQmain","IE00B3QW5Z07.USD","QID","VYNE","BK4585","PSQ","QLD","BK4007","TQQQ",".IXIC"],"gpt_icon":1},{"id":"2467739949","title":"Buy Rating for VYNE Therapeutics Backed by Promising Early Phase Results and Strong Clinical Development Trajectory","url":"https://stock-news.laohu8.com/highlight/detail?id=2467739949","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467739949?lang=en_us&edition=fundamental","pubTime":"2024-09-13 04:25","pubTimestamp":1726172719,"startTime":"0","endTime":"0","summary":"VYNE Therapeutics (VYNE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Rami Katkhuda from...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-for-vyne-therapeutics-backed-by-promising-early-phase-results-and-strong-clinical-development-trajectory?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-for-vyne-therapeutics-backed-by-promising-early-phase-results-and-strong-clinical-development-trajectory?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYNE"],"gpt_icon":0},{"id":"2466208633","title":"Buy Rating Affirmed for VYNE Therapeutics Amid Promising Early Data for VYN202","url":"https://stock-news.laohu8.com/highlight/detail?id=2466208633","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466208633?lang=en_us&edition=fundamental","pubTime":"2024-09-12 21:25","pubTimestamp":1726147520,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on VYNE Therapeutics (VYNE – Research Report) today and set a price target of $5.7...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-vyne-therapeutics-amid-promising-early-data-for-vyn202?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-vyne-therapeutics-amid-promising-early-data-for-vyn202?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYNE"],"gpt_icon":0},{"id":"2466627279","title":"Vyne Therapeutics Inc: Vyn202 Was Generally Well Tolerated With No Drug-Related Adverse Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2466627279","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466627279?lang=en_us&edition=fundamental","pubTime":"2024-09-12 20:03","pubTimestamp":1726142607,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240912:nFWN3KU0IE:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VYNE","BK4007"],"gpt_icon":0},{"id":"2466027962","title":"Vyne Therapeutics Inc: Positive Phase 1a Sad Data for Vyn202, a Novel Bd2-Selective Bet Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2466027962","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466027962?lang=en_us&edition=fundamental","pubTime":"2024-09-12 20:03","pubTimestamp":1726142607,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240912:nFWN3KU0IE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VYNE","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vynetherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0234},{"period":"1month","weight":-0.1135},{"period":"3month","weight":0.2563},{"period":"6month","weight":0.3736},{"period":"1year","weight":-0.0157},{"period":"ytd","weight":0.073}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.103241},{"month":2,"riseRate":0.285714,"avgChangeRate":-0.000108},{"month":3,"riseRate":0.428571,"avgChangeRate":0.048397},{"month":4,"riseRate":0.142857,"avgChangeRate":-0.184881},{"month":5,"riseRate":0.571429,"avgChangeRate":0.038029},{"month":6,"riseRate":0,"avgChangeRate":-0.163623},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.064684},{"month":8,"riseRate":0.142857,"avgChangeRate":-0.080327},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.032924},{"month":10,"riseRate":0.428571,"avgChangeRate":0.003758},{"month":11,"riseRate":0.428571,"avgChangeRate":-0.045576},{"month":12,"riseRate":0.142857,"avgChangeRate":-0.147093}],"exchange":"NASDAQ","name":"VYNE Therapeutics Inc.","nameEN":"VYNE Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"VYNE Therapeutics Inc.(VYNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest VYNE Therapeutics Inc.(VYNE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"VYNE Therapeutics Inc.,VYNE,VYNE Therapeutics Inc.股票,VYNE Therapeutics Inc.股票老虎,VYNE Therapeutics Inc.股票老虎国际,VYNE Therapeutics Inc.行情,VYNE Therapeutics Inc.股票行情,VYNE Therapeutics Inc.股价,VYNE Therapeutics Inc.股市,VYNE Therapeutics Inc.股票价格,VYNE Therapeutics Inc.股票交易,VYNE Therapeutics Inc.股票购买,VYNE Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"VYNE Therapeutics Inc.(VYNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest VYNE Therapeutics Inc.(VYNE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}